MINNEAPOLIS, May 28 /PRNewswire-FirstCall/ -- Uroplasty, Inc. announced today that it will release financial results for the fourth quarter and the fiscal year ended March 31, 2008, at the market close on Tuesday, June 3, 2008. The Company will host a conference call to discuss these results on Tuesday, June 3, 2008 at 3:30 p.m. Central Time. David Kaysen, President and Chief Executive Officer, and Medi Jiwani, Vice President, Chief Financial Officer and Treasurer, will host the call. Individuals wishing to participate in the conference call should dial 800-218-0204 (domestic) or 303-262-2130 (international). An audio replay will be available for thirty days following the call at 800-405-2236 (domestic) or 303-590-3000 (international), with the passcode 11115072#.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our primary focus is the commercialization of our Urgent PC(R) system, which we believe is the only FDA-approved minimally invasive nerve stimulation device designed for office-based treatment of symptoms often associated with overactive bladder. We also offer Macroplastique(R) Implants, a bulking agent for the treatment of urinary incontinence. Please visit Uroplasty, Inc. at http://www.uroplasty.com.
CONTACT: David Kaysen, President and CEO, or Medi Jiwani, Vice President,
CFO, and Treasurer, both of Uroplasty, Inc., +1-952-426-6140; or Investors,
Dahlia Baliey, +1-415-896-6820, or Media, Chris Gale, +1-646-201-5445, both
of EVC Group for Uroplasty, Inc.
Web site: http://www.uroplasty.com//
